Year-end Sale % OFF 
Abstract
Poststroke depression is one of the common psychiatric complications after stroke. Thus, the research of new ways for treatment depressed mood after stroke is actual. The previous researches revealed vasopressin to be effective in patients with memory, speech and motor function disorders after stroke. The purpose of the study was to investigate influence of vasopressin on depression after stroke. Fourteen patients with affective disorders have been treated with subendocrine doses of 1-desamino-8-D-arginin-vasopressin (DDAVP) daily by intranasal application during 1,5-2 months. Vasopressin was effective in correcting both apatoadinamic and anxious depression. Treatment effect was durable, lasts for 0,5-1 year after the first course of therapy. The results of this pilot study demonstrate perspective of using selective agonist of vasopressin V2 receptors, DDAVP, in therapy of post-stroke depression.
Highlights
Постинсультная депрессия — наиболее частое психическое осложнение инсульта
Fourteen patients with affective disorders have been treated with subendocrine doses of 1-desamino-8-D-arginin-vasopressin (DDAVP) daily by intranasal application during 1,5–2 months
Для объяснения полученных данных следует иметь в виду, что депрессивные расстройства обусловлены дефицитом и/или дисбалансом в головном мозге нейромеди-
Summary
Постинсультная депрессия — наиболее частое психическое осложнение инсульта. В этой связи актуален поиск новых методов лечения таких расстройств. Agonist of V2 vasopressin receptor reduces depressive disorders in post-stroke patients The results of this pilot study demonstrate perspective of using selective agonist of vasopressin V2 receptors, DDAVP, in therapy of post-stroke depression. Эффект плацебо (интраназальное введение уровня глюкокортикоидов в плазме крови, секрецией физиологического раствора в течение 1 нед) оценивали кортикотропин-рилизинг гормона (КТРГ) и адренокор- у тех же 14 больных перед проведением курса терапии тикотропного гормона (АКТГ).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
